Pathogenesis of HIV-associated cardiovascular disease

Advances in Cardiology

Volumn 40, Issue , 2003, Pages 49-70

  Barbara, Giuseppe ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; AUTOIMMUNITY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; HEART MUSCLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW; RISK ASSESSMENT; VASCULAR ENDOTHELIUM; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUTOIMMUNITY; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CARDIOVASCULAR DISEASES; CORONARY DISEASE; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; MYOCARDIUM; NEOPLASMS; PROTEASE INHIBITORS; RISK ASSESSMENT;

EID: 0242367419     PISSN: 00652326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Barbaro G: Cardiovascular manifestations of HIV infection. Circulation 2002;106:1420-1425.
2. Barbaro G, Di Lorenzo G, Soldini M, et al: Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Circulation 1999;100:933-999.
3. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D: Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000;40:282-284.
4. Shannon RP, Simon MA, Mathier MA, Geng YJ, Mankad S, Lackner AA: Dilated cardiomyopathy associated with simian AIDS in nonhuman primates. Circulation 2000;101:185-193.
5. Bijl M, Dieleman JP, Simoons M, Van der Ende ME: Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy. J AIDS 2001;27: 318-320.
6. Barbaro G, Di Lorenzo G, Soldini M, Grisorio B, Barbarini G: Cardiac involvement in the acquired immunodeficiency syndrome: A clinical-pathological study (abstract). Circulation 1999; 96:1-646.
7. Barbara G, Di Lorenzo G, Grisorio B, Barbarini G, and the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS investigators: Cardiac involvement in the acquired immunodeficiency syndrome: A multicenter clinical-pathological study. AIDS Res Hum Retroviruses 1998;14:1071-1077.
8. Currie PF, Goldman JH, Caforio AL, et al: Cardiac autoimmunity in HIV related heart muscle disease. Heart 1998;79:599-604.
9. Lipshultz SE, Easley KA, Orav EJ, et al: Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Circulation 2000;102:1542-1548.
10. Freeman GL, Colston JT, Zabalgoitia M, Chandrasekar B: Contractile depression and expression of proinflammatory cytokines and iNOS in viral myocarditis. Am J Physiol 1998;274:249-258.
11. Lipshultz SE, Easley KA, Orav EJ, et al: Left ventricular structure and function in children infected with human immunodeficiency virus: The prospective P2C2 HIV Multicenter Study. Circulation 1998;97:1246-1256.
12. Cooper ER, Hanson C, Diaz C, et al: Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. J Pediatr 1998;132:808-812.
13. Barbara G, Di Lorenzo G, Soldini M, et al: Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of TNF-α and iNOS. AIDS 2000;14:827-838.
14. Miller TL, Orav EJ, Colan SD, Lipshultz SE: Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. Am J Clin Nutr 1997;66:660-664.
15. Miller TL: Cardiac complications of nutritional disorders; in Lipshultz SE (ed): Cardiology in AIDS. New York, Chapman & Hall, 1998, pp 307-316.
16. Hoffman M, Lipshultz SE, Miller TL: Malnutrition and cardiac abnormalities in the HIV-infected patients; in Miller TL, Gorbach S (eds): Nutritional Aspects of HIV Infection. London, Arnold, 1999, pp 33-39.
17. Lewis W, Simpson JF, Meyer RR: Cardiac mitochondrial DNA polymerase gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 1994;74:344-348.
18. Lewis W, Grupp IL, Grupp G, et al: Cardiac dysfunction in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000;80:187-197.
19. Lipshultz SE, Easley KA, Orav EJ, et al: Absence of cardiac toxicity of zidovudine in infants. N Engl J Med 2000;343:759-766.
20. Barbara G, Fisher SD, Giancaspro G, Lipshultz SE: HIV-associated cardiovascular complications: A new challenge for emergency physicians. Am J Emerg Med 2001;19:566-574.
21. Ohtsuka T, Hamada M, Hiasa G, et al: Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2000;37:412-417.
22. Johnson RM, Little JR, Storch GA: Kawasaki-like syndromes associated with human immunodeficiency virus infection. Clin Infect Dis 2001;32:1628-1634.
23. Shingadia D, Das L, Klein-Gitelman M, Chadwick E: Takayasu's arteritis in a human immunodeficiency virus-infected adolescent. Clin Infect Dis 1999;29:458-459.
24. Gisselbrecht M: Vasculitis during human acquired immunodeficiency virus infection. Pathol Biol (Paris) 1999;47:245-247.
25. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G: The effects of HIV infection on endothelial function. Endothelium 2000;7:223-242.
26. Berger O, Gan X, Gujuluva C, et al: CXC and CC chemokine receptors on coronary and brain endothelia. Mol Med 1999;5:795-805.
27. Twu C, Liu QN, Popik W, et al: Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion and death receptor-controlled pathways. Proc Natl Acad Sci USA 2002;99:14386-14391.
28. Grahame-Clarke C, Alber DG, Lucas SB, Miller R, Vallance P: Association between Kaposi's sarcoma and atherosclerosis: Implications for gammaherpesviruses and vascular disease. AIDS 2001;15:1902-1905.
29. Barbara G, Barbarini G, Pellicelli AM: HIV-associated coronary arteritis in a patient with fatal myocardial infarction. N Engl J Med 2001;344:1799-1800.
30. Barbara G, Klatt EC: HIV infection and the cardiovascular system. AIDS Rev 2002;4:93-103.
31. Behrens GM, Stoll M, Schmidt RE: Lipodystrophy and metabolic disorders in anti-HIV therapy. MMW Fortschr Med 2000;142(suppl 1):68-71.
32. Vigoureux C, Gharakhanian S, Salhi Y, et al: Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999;25:225-232.
33. John M, Nolan D, Mallal S: Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001;6:9-20.
34. Nolan D, Mallal S: Getting to the HAART of insulin resistance. AIDS 2001;15:2037-2041.
35. Periard D, Telenti A, Sudre P, et al: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: The Swiss HIV Cohort Study. Circulation 1999;100:700-705.
36. Assmann G, Schulte H, Von Eckardstein K: Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77: 1178-1179.
37. Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-1-protease inhibitorassociated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351: 1881-1883.
38. Carr A, Samaras K, Burton S, et al: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
39. Mooser V, Carr A: Antiretroviral therapy-associated hyperlipidemia in HIV disease. Curr Opin Lipidol 2001;12:313-319.
40. Fauvel J, Bonnet E, Ruidavets JB, et al: An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001;15: 2397-2406.
41. Bonnet E, Ruidavets JB, Tuech J, et al: Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophy. J Clin Endocrinol Metab 2001;86:296-302.
42. Gaou I, Malliti M, Guimont MC, et al: Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther 2001;297:516-523.
43. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-20254.
44. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC: Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000;25:312-321.
45. Stein JH, Klein MA, Bellehumeur JL, et al: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-262.
46. Behrens GM, Stoll M, Schmidt RE: Lipodystrophy syndrome in HIV infection: What is it, what causes it and how can it be managed? Drug Saf 2000;23:57-76.
47. Smith D: Clinical significance of treatment-induced lipid abnormalities and lipodystrophy. J HIV Ther 2001;6:25-27.
48. Dube MP, Sprecher D, Henry WK, et al: Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000;31:1216-1224.
49. Volberding P, Murphy R, Barbare G, et al: The Pavia Consensus Statement. AIDS 2003;17 (suppl 1):S170-S179.
50. Moyle G, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG: Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 2001;15:1503-1508.
51. Carr A, Hudson J, Chuan J, et al: HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS 2001;15:1811-1822.
52. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, et al: Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-1526.
53. Ruiz L, Negredo E, Domingo P, et al: Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J AIDS 2001;27:229-236.
54. van der Valk M, Kastelein JJP, Murphy RL, et al: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-2414.
55. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE: Vascular complications associated with use of HIV protease inhibitors (letter). Lancet 1998;351:1958.
56. Rickerts V, Brodt H, Staszewski S, Stille W: Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: The Frankfurt HIV Cohort Study. Eur J Med Res 2000;5:329-333.
57. Holmberg SD, Moorman AC, Williamson JM, et al: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-1748.
58. Friis-Moller N, Weber R, Reiss P, et al: Cardiovascular risk factors in HIV patients - Association with antiretroviral therapy. Results from DAD study. AIDS 2003;17:1179-1193.
59. Barbara G: Increased access to the emergency department for coronary heart disease of HIV-infected patients receiving highly active antiretroviral therapy. Ann Emerg Med 2002;40:530-531.
60. Barbara G, Di Lorenzo G, Grisorio B, Barbarini G: Incidence of coronary heart disease in HIV-infected patients receiving HAART with or without protease inhibitors: A prospective multicenter study (abstract). Circulation 2002;106(suppl 2):II-414.
61. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-710.
62. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J AIDS 2002;30:471-477.
63. Coplan P, Cormier K, Japour A, et al: Myocardial infarction incidence in clinical trials of 4 protease inhibitors (abstract 34). 7th Conf Retroviruses Opportunistic Infect, San Francisco, 2000.
64. Coplan P, Nikas A, Leavit RY, et al: Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials. AIDS 2001;15:1584-1586.
65. Varriale P, Mirzai-Tehrane M, Sedighi A: Acute myocardial infarction associated with anabolic steroids in a young HIV-infected patient. Pharmacotherapy 1999;19:881-884.
66. Depairon M, Chessex S, Sudre P, et al: Premature atherosclerosis in HIV-infected individuals: Focus on protease inhibitor therapy. AIDS 2001;15:329-334.
67. Maggi P, Serio G, Epifani G, et al: Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000;14:F123-F128.
68. Aoun S, Ramos E: Hypertension in the HIV-infected patient. Curr Hypertens Rep 2000;2: 478-481.
69. Nair R, Robbs JV, Chetty R, Naidoo NG, Woolgar J: Occlusive arterial disease in HIV-infected patients: A preliminary report. Eur J Vase Endovasc Surg 2000;20:353-357.
70. Raine AE: Hypertension, blood viscosity and cardiovascular morbidity in renal failure: Implication of erythropoietin therapy. Lancet 1988;1:97-100.
71. Sattler FR, Qian D, Louie S, et al: Elevated blood pressure in subjects with lipodystrophy. AIDS 2001;15:2001-2010.
72. Witz M, Lehmann J, Korzets Z: Acute brachial artery thrombosis as the initial manifestation of human immunodeficiency virus infection. Am J Hematol 2000;64:137-139.
73. Hadigan C, Meigs JB, Rabe J, et al: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001;86:939-943.
74. Sullivan PS, Dworkin MS, Jones JL, Hooper WC: Epidemiology of thrombosis in HIV-infected individuals: The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000;14:321-324.
75. Barbara G, Fisher SD, Lipshultz SE: Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 2001;1:115-124.
76. Arsura EL, Ismail Y, Freeman S, Karunakav AR: Amphotericin B-induced dilated cardiomyopathy. Am J Med 1994;97:560-562.
77. Cohen AJ, Weiser B, Afzal Q, Fuhrer J: Ventricular tachycardia in two patients with AIDS receiving ganciclovir (DHPG). AIDS 1990;4:807-809.
78. Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T: QT prolongation and torsade de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 1987;59:376-377.
79. Stein KM, Haronian H, Mensah GA, Acosta A, Jacobs J, Klingfield P: Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am J Cardiol 1990;66:888-889.
80. Duong M, Dubois C, Buisson M, et al: Non-Hodgkin's lymphoma of the heart in patients infected with human immunodeficiency virus. Clin Cardiol 1997;20:497-502.
81. Sanna P, Bertoni F, Zucca E, et al: Cardiac involvement in HIV-related non-Hodgkin's lymphoma: A case report and short review of the literature. Ann Hematol 1998;77:75-78.
82. Dal Maso L, Serraino D, Franceschi S: Epidemiology of HIV-associated malignancies. Cancer Treat Res 2001;104:1-18.
83. Barbara G, Di Lorenzo G, Grisorio B, Barbarini G for the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS investigators: Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV positive patients. N Engl J Med 1998;339:1093-1099.
84. Heidenreich PA, Eisenberg MJ, Kee LL, et al: Pericardial effusion in AIDS: Incidence and survival. Circulation 1995;92:3229-3234.